Lido Advisors’s Esperion Therapeutics ESPR Stock Holding History

Lido Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-99,139	Closed	-$272K	–	2177
2026 Q1	$272K	Buy	+99,139	New	+$314K	﹤0.01%	1616

Other funds holding ESPR

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Lido Advisors's ESPR Position: Q2 2026 in Review

Lido Advisors sold out of Esperion Therapeutics (ESPR) in Q2 2026, closing a stake of 99,139 shares — an estimated $272K sold.

Lido Advisors first reported a position in ESPR in Q1 2026 and held it in 1 quarter. The position peaked at $272K in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Lido Advisors reported no remaining Esperion Therapeutics position as of Q2 2026 after selling out during the quarter.
Lido Advisors sold 99,139 Esperion Therapeutics shares in Q2 2026, an estimated $272K.
Lido Advisors first reported a position in Esperion Therapeutics in Q1 2026 and held it in 1 quarter.
Lido Advisors's Esperion Therapeutics position peaked at $272K in Q1 2026.
191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.